Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.

MLA

Kalra, Sanjay, et al. “Comment on Udell et Al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.” Diabetes Care, vol. 38, no. 6, June 2015, pp. e88–89. EBSCOhost, https://doi.org/10.2337/dc15-0006.

APA

Kalra, S., Gupta, Y., Baruah, M. P., & Gupta, A. (2015). Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705. Diabetes Care, 38(6), e88–e89. https://doi.org/10.2337/dc15-0006

Chicago

Kalra, Sanjay, Yashdeep Gupta, Manash P Baruah, and Anu Gupta. 2015. “Comment on Udell et Al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.” Diabetes Care 38 (6): e88–89. doi:10.2337/dc15-0006.